-
Signature
-
/s/ Gilmore O'Neill
-
Issuer symbol
-
EDIT
-
Transactions as of
-
12 Mar 2026
-
Net transactions value
-
$0
-
Form type
-
4
-
Filing time
-
16 Mar 2026, 16:37:09 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| O'Neill Gilmore Neil |
CEO, Director |
C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE |
/s/ Gilmore O'Neill |
16 Mar 2026 |
0001742084 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
EDIT |
Stock Option (right to buy) |
Award |
|
+1,015,200 |
|
$0.000000* |
1,015,200 |
12 Mar 2026 |
Common Stock |
1,015,200 |
$2.54 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: